Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Cancer Immunol Res. 2021 Mar;9(3):255-260. doi: 10.1158/2326-6066.CIR-20-0791.
The success of immune-checkpoint blockade and chimeric antigen receptor (CAR) T cell therapies has established the remarkable capacity of the immune system to fight cancer. Over the past several years, it has become clear that immune cell responses to cancer are critically dependent upon metabolic programs that are specific to both immune cell type and function. Metabolic features of cancer cells and the tumor microenvironment impose constraints on immune cell metabolism that can favor immunosuppressive phenotypes and block antitumor responses. Advances in both preclinical and clinical studies have demonstrated that metabolic interventions can dramatically enhance the efficacy of immune-based therapies for cancer. As such, understanding the metabolic requirements of immune cells in the tumor microenvironment, as well as the limitations imposed therein, can have significant benefits for informing both current practice and future research in cancer immunotherapy.
免疫检查点阻断和嵌合抗原受体 (CAR) T 细胞疗法的成功确立了免疫系统对抗癌症的显著能力。在过去的几年中，人们已经清楚地认识到，免疫细胞对癌症的反应严重依赖于免疫细胞类型和功能特有的代谢程序。癌细胞和肿瘤微环境的代谢特征对免疫细胞代谢施加了限制，这些限制有利于免疫抑制表型并阻止抗肿瘤反应。临床前和临床研究的进展表明，代谢干预可以显著增强免疫疗法治疗癌症的疗效。因此，了解肿瘤微环境中免疫细胞的代谢需求以及其中的限制因素，对于为癌症免疫治疗的当前实践和未来研究提供信息具有重要意义。
